Initiating and selecting biologic therapy for IBD: A faculty roundtable discussion

Program overview

The mainstay biologic therapy for IBD is anti-TNF therapy, based on clinical trial data, long-term follow-up data, and personal patient and physician experience. However, with the approval in 2014 of vedolizumab for ulcerative colitis (UC) and Crohn's disease (CD), the treatment algorithm has become more complex. Using a roundtable format, this IBD Dialog will provide expert-led discussion on when to consider a biologic therapy, and "tips and pointers" for the selection of therapy (anti-TNF vs anti-integrin).

Target audience

This activity has been designed to meet the educational needs of gastroenterologists and registered nurses involved in the care of patients with inflammatory bowel disease (IBD).

Release date: August 19, 2015
Expiry date: August 19, 2016

Learning objectives

After completing this activity, the participant should be better able to:

  • Discuss factors to consider when initiating a first biologic in CD and UC
  • Evaluate the different biologics available for first line therapy
  • Summarize the principles for monotherapy vs combination therapy in IBD
  • Provide appropriate care and counsel for patients and their families.

Faculty

Gary R. Lichtenstein, MD
Professor of Medicine
Director, Center for Inflammatory Bowel Disease
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Biography

Miguel D. Regueiro, MD
Professor of Medicine
Associate Chief for Education
Co-Director, Inflammatory Bowel Disease Center
University of Pittsburgh
Pittsburgh, PA

Biography

Bruce E. Sands, MD, MS
Chief of the Dr. Henry D. Janowitz Division of Gastroenterology
Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, NY

Biography

Syllabus disclosure statement

Disclosure of conflicts of interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter

Reported Financial Relationship

Gary R. Lichtenstein

Advisor or consultant for: Abbott Laboratories, Centocor Ortho Biotech Inc., Elan Pharmaceuticals, Inc., Ferring Pharmaceuticals, Genentech, Inc., Meda Pharmaceuticals, Inc., Merck & Co., Inc., Millennium Pharmaceuticals, Inc., Pfizer Inc., Procter & Gamble, Prometheus Laboratories Inc., Salix Pharmaceuticals, Inc., Santarus, Inc., Schering-Plough Corporation, Shire, Therakos, Inc., UCB Pharma, Inc., Warner Chilcott, Wyeth Pharmaceuticals Inc.

Received grants for clinical research from: Bristol-Myers Squibb, Centocor Ortho Biotech Inc., Ferring Pharmaceuticals, Meda Pharmaceuticals, Inc., Procter & Gamble, Prometheus Laboratories Inc., Salix Pharmaceuticals, Inc., Shire, Therakos, Inc., UCB Pharma, Inc., Warner Chilcott

Miguel D. Regueiro

Consulting fees: AbbVie, Janssen, Shire, Takeda, UCB

Bruce E. Sands

Consulting : AbbVie, Forest Research Institute, Rockpointe, Salix, Shire, Strategic Consultants international, Tigenix

Consultant (service on a scientific advisory board): Bristol-Myers Squibb, Celgene, Janssen Biotech, Luitpold Pharmaceuticals, MedImmune, Millennium Pharmaceuticals, Pfizer, Prometheus Laboratories

Honoraria: American Academy of CME, Inc., ACG, AGA, AGA Institute, Catrille & Associates, Ltd., Focus Medical Communications, IMEDEX, Jefferson University, University Health Network, Vindico Medical Education

Research Grants: Janssen Biotech, MedImmune, Pfizer, Prometheus Laboratories,

Other: Avaxia Biologics (shares in a non-publicly traded company)


The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following SCI planners and managers, Ian Morgan, MSc, and Elena Urso, BSc, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity or any amount during the past 12 months.

Accreditation

Physician continuing education

Accreditation statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Strategic Consultants International. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing continuing education

Credit designation

This educational activity for 1.2 contact hours is provided by Postgraduate Institute for Medicine.

Accreditation statement

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Estimated time to complete activity: 75 minutes

Disclosure of unlabeled use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of participation and request for credit

There are no fees for participating and receiving CME/CE credit for this activity. To successfully earn credit, participants must complete the activity online during the valid credit period. Follow these steps to earn CME/CE credit:

  1. Read the target audience, learning objectives, and author disclosures
  2. View the educational content online
  3. Upon completion of the activity, complete the online posttest and Activity Evaluation to provide feedback for future programming.

Upon successful completion of the posttest, with a score of 75% or better, and the online Evaluation form, you will have immediate access to a certificate of attendance to print or save for your files.

If you have any questions regarding the CME/CE certification for this activity, please contact Postgraduate Institute for Medicine at: information@pimed.com or (303) 799-1930.

Media: Internet

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Jointly provided by the Postgraduate Institute for Medicine and
Strategic Consultants International
PIM Logo  
This activity is supported by an independent educational grant from
Takeda Pharmaceuticals International, Inc., US Region,
UCB, Inc., and Prometheus.
Continue